Preferred Label : Trastuzumab Rezetecan;
NCIt synonyms : Anti-HER2 ADC BAT8001; ADC SHR-A1811; Anti-HER2 ADC SHR-A1811; Anti-HER2 Antibody-drug Conjugate SHR-A1811;
NCIt definition : An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin
G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen
(TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via
a cleavable linker, to rezetecan, an exatecan derivative and topoisomerase 1 inhibitor,
with potential antineoplastic activity. Upon administration of trastuzumab rezetecan,
the trastuzumab moiety targets and binds to HER2 expressed on tumor cells. Upon cellular
uptake and linker cleavage, rezetecan stabilizes covalent topoisomerase I-DNA complexes,
and results in single-stranded and double-stranded DNA breaks, the inhibition of DNA
replication, the induction of apoptosis and the inhibition of tumor cell proliferation
in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed
by many cancer cell types.;
UNII : 1000BJC8CR;
CAS number : 2647845-11-0;
Molecule name : SHR-A1811; SHR A1811;
NCI Metathesaurus CUI : CL1647822;
Origin ID : C178312;
UMLS CUI : C5706700;
Semantic type(s)
- concept_is_in_subset
- has_target
